Wave Life Sciences Ltd., a biotechnology company, designs, develops, and commercializes nucleic acid therapeutic candidates for genetically defined diseases by utilizing proprietary synthetic chemistry drug development platform. The company is primarily developing oligonucleotides that target genetic defects to either reduce the expression of disease-promoting proteins or transform the production of dysfunctional mutant proteins into the production of functional proteins. It focuses on proprietary programs in neurology in the central nervous system and neuromuscular system. The company has a research, license, and option agreement with Pfizer Inc. and Takeda Pharmaceutical Company Limited for the research, development, and commercialization of stereopure oligonucleotide therapeutics and oligonucleotide therapeutics, as well as a collaboration agreement with Deep Genomics Inc. for identifying novel therapies. Wave Life Sciences Ltd. was founded in 2012 and is based in Singapore.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:WVE
CUSIPN/A
Phone65-6236-3388
Debt
Debt-to-Equity Ratio0.04
Current Ratio7.24
Quick Ratio7.24
Price-To-Earnings
Trailing P/E Ratio-10.14
Forward P/E Ratio-8.17
P/E GrowthN/A
Sales & Book Value
Annual Sales$3.70 million
Price / Sales309.13
Cash FlowN/A
Price / CashN/A
Book Value$5.03 per share
Price / Book7.76
Profitability
EPS (Most Recent Fiscal Year)($3.85)
Net Income$-102,030,000.00
Net Margins-2,613.03%
Return on Equity-76.93%
Return on Assets-61.14%
Miscellaneous
Employees168
Outstanding Shares29,290,000
Market Cap$1,143.89
Wave Life Sciences (NASDAQ:WVE) Frequently Asked Questions
What is Wave Life Sciences' stock symbol?
Wave Life Sciences trades on the NASDAQ under the ticker symbol "WVE."
How were Wave Life Sciences' earnings last quarter?
Wave Life Sciences Ltd (NASDAQ:WVE) issued its earnings results on Wednesday, May, 9th. The company reported ($1.26) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.90) by $0.36. The company earned $1.42 million during the quarter, compared to analyst estimates of $6.59 million. Wave Life Sciences had a negative net margin of 2,613.03% and a negative return on equity of 76.93%. View Wave Life Sciences' Earnings History.
When is Wave Life Sciences' next earnings date?
What price target have analysts set for WVE?
4 brokerages have issued 1-year price objectives for Wave Life Sciences' stock. Their forecasts range from $40.00 to $65.00. On average, they expect Wave Life Sciences' stock price to reach $56.75 in the next year. This suggests a possible upside of 45.3% from the stock's current price. View Analyst Ratings for Wave Life Sciences.
What is the consensus analysts' recommendation for Wave Life Sciences?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Wave Life Sciences in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
Who are some of Wave Life Sciences' key competitors?
Some companies that are related to Wave Life Sciences include HUTCHISON CHINA/S (HCM), Taro Pharmaceutical Industries (TARO), Ultragenyx Pharmaceutical (RARE), Madrigal Pharmaceuticals (MDGL), GW Pharmaceuticals PLC- (GWPH), Array Biopharma (ARRY), OPKO Health (OPK), Ironwood Pharmaceuticals (IRWD), Amicus Therapeutics (FOLD), Evotec (EVTCY), The Medicines (MDCO), Horizon Pharma (HZNP), Ascendis Pharma A/S (ASND), Supernus Pharmaceuticals (SUPN) and Heron Therapeutics (HRTX).
Who are Wave Life Sciences' key executives?
Wave Life Sciences' management team includes the folowing people:
- Dr. Paul B. Bolno, Pres, CEO & Director (Age 44)
- Mr. Keith Regnante, Chief Financial Officer (Age 48)
- Dr. Michael A. Panzara, Franchise Lead of Neurology (Age 51)
- Dr. Takeshi Wada, Scientific Advisor (Age 56)
- Mr. Kyle B. Moran, Sr. VP of Supply Chain & Operations (Age 47)
Has Wave Life Sciences been receiving favorable news coverage?
Media headlines about WVE stock have trended somewhat positive recently, Accern Sentiment reports. Accern ranks the sentiment of press coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Wave Life Sciences earned a coverage optimism score of 0.15 on Accern's scale. They also assigned news stories about the company an impact score of 46.13 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company's share price in the near term.
How do I buy shares of Wave Life Sciences?
Shares of WVE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Wave Life Sciences' stock price today?
One share of WVE stock can currently be purchased for approximately $39.05.
How big of a company is Wave Life Sciences?
Wave Life Sciences has a market capitalization of $1.14 billion and generates $3.70 million in revenue each year. The company earns $-102,030,000.00 in net income (profit) each year or ($3.85) on an earnings per share basis. Wave Life Sciences employs 168 workers across the globe.
How can I contact Wave Life Sciences?
Wave Life Sciences' mailing address is 7 STRAITS VIEW #12-00 MARINA ONE EAST TOWER, SINGAPORE U0, 018936. The company can be reached via phone at 65-6236-3388 or via email at [email protected]
MarketBeat Community Rating for Wave Life Sciences (NASDAQ WVE)
MarketBeat's community ratings are surveys of what our community members think about Wave Life Sciences and other stocks. Vote "Outperform" if you believe WVE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe WVE will underperform the S&P 500 over the long term. You may vote once every thirty days.
